Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Inhibition of synaptic transmission by anandamide precursor 20:4-NAPE is mediated by TRPV1 receptors under inflammatory conditions

D. Spicarova, V. Nerandzic, D. Muzik, M. Pontearso, A. Bhattacharyya, I. Nagy, J. Palecek

. 2023 ; 16 (-) : 1188503. [pub] 20230622

Status not-indexed Language English Country Switzerland

Document type Journal Article

Transient receptor potential ion channel, vanilloid subfamily, type 1 (TRPV1) cation channel, and cannabinoid receptor 1 (CB1) are essential in the modulation of nociceptive signaling in the spinal cord dorsal horn that underlies different pathological pain states. TRPV1 and CB1 receptors share the endogenous agonist anandamide (AEA), produced from N-arachidonoylphosphatidylethanolamine (20:4-NAPE). We investigated the effect of the anandamide precursor 20:4-NAPE on synaptic activity in naive and inflammatory conditions. Patch-clamp recordings of miniature excitatory postsynaptic currents (mEPSCs) from superficial dorsal horn neurons in rat acute spinal cord slices were used. Peripheral inflammation was induced by subcutaneous injection of carrageenan. Under naive conditions, mEPSCs frequency (0.96 ± 0.11 Hz) was significantly decreased after 20 μM 20:4-NAPE application (55.3 ± 7.4%). This 20:4-NAPE-induced inhibition was blocked by anandamide-synthesizing enzyme N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) inhibitor LEI-401. In addition, the inhibition was prevented by the CB1 receptor antagonist PF 514273 (0.2 μM) but not by the TRPV1 receptor antagonist SB 366791 (10 μM). Under inflammatory conditions, 20:4-NAPE (20 μM) also exhibited a significant inhibitory effect (74.5 ± 8.9%) on the mEPSCs frequency that was prevented by the TRPV1 receptor antagonist SB 366791 but not by PF 514273 application. Our results show that 20:4-NAPE application has a significant modulatory effect on spinal cord nociceptive signaling that is mediated by both TRPV1 and CB1 presynaptic receptors, whereas peripheral inflammation changes the underlying mechanism. The switch between TRPV1 and CB1 receptor activation by the AEA precursor 20:4-NAPE during inflammation may play an important role in nociceptive processing, hence the development of pathological pain.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015868
003      
CZ-PrNML
005      
20231020093438.0
007      
ta
008      
231010s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fnmol.2023.1188503 $2 doi
035    __
$a (PubMed)37426071
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Spicarova, Diana $u Laboratory of Pain Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia
245    10
$a Inhibition of synaptic transmission by anandamide precursor 20:4-NAPE is mediated by TRPV1 receptors under inflammatory conditions / $c D. Spicarova, V. Nerandzic, D. Muzik, M. Pontearso, A. Bhattacharyya, I. Nagy, J. Palecek
520    9_
$a Transient receptor potential ion channel, vanilloid subfamily, type 1 (TRPV1) cation channel, and cannabinoid receptor 1 (CB1) are essential in the modulation of nociceptive signaling in the spinal cord dorsal horn that underlies different pathological pain states. TRPV1 and CB1 receptors share the endogenous agonist anandamide (AEA), produced from N-arachidonoylphosphatidylethanolamine (20:4-NAPE). We investigated the effect of the anandamide precursor 20:4-NAPE on synaptic activity in naive and inflammatory conditions. Patch-clamp recordings of miniature excitatory postsynaptic currents (mEPSCs) from superficial dorsal horn neurons in rat acute spinal cord slices were used. Peripheral inflammation was induced by subcutaneous injection of carrageenan. Under naive conditions, mEPSCs frequency (0.96 ± 0.11 Hz) was significantly decreased after 20 μM 20:4-NAPE application (55.3 ± 7.4%). This 20:4-NAPE-induced inhibition was blocked by anandamide-synthesizing enzyme N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) inhibitor LEI-401. In addition, the inhibition was prevented by the CB1 receptor antagonist PF 514273 (0.2 μM) but not by the TRPV1 receptor antagonist SB 366791 (10 μM). Under inflammatory conditions, 20:4-NAPE (20 μM) also exhibited a significant inhibitory effect (74.5 ± 8.9%) on the mEPSCs frequency that was prevented by the TRPV1 receptor antagonist SB 366791 but not by PF 514273 application. Our results show that 20:4-NAPE application has a significant modulatory effect on spinal cord nociceptive signaling that is mediated by both TRPV1 and CB1 presynaptic receptors, whereas peripheral inflammation changes the underlying mechanism. The switch between TRPV1 and CB1 receptor activation by the AEA precursor 20:4-NAPE during inflammation may play an important role in nociceptive processing, hence the development of pathological pain.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nerandzic, Vladimir $u Laboratory of Pain Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Muzik, David $u Laboratory of Pain Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Pontearso, Monica $u Laboratory of Pain Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Bhattacharyya, Anirban $u Laboratory of Pain Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Nagy, Istvan $u Section of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, Chelsea and Westminster Hospital, London, United Kingdom $u Department of Physiology, University of Debrecen, Debrecen, Hungary
700    1_
$a Palecek, Jiri $u Laboratory of Pain Research, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia
773    0_
$w MED00163316 $t Frontiers in molecular neuroscience $x 1662-5099 $g Roč. 16, č. - (2023), s. 1188503
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37426071 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093431 $b ABA008
999    __
$a ok $b bmc $g 1997298 $s 1202230
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 16 $c - $d 1188503 $e 20230622 $i 1662-5099 $m Frontiers in molecular neuroscience $n Front Mol Neurosci $x MED00163316
LZP    __
$a Pubmed-20231010

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...